🫁 Tuberculosis Vaccine Tracker

Tracking M72/AS01E, VPM1002, MTBVAC & Next-Generation TB Vaccines

Updated July 2026. Tuberculosis (TB) kills 1.3 million people annually, making it the world's deadliest infectious disease. The only licensed vaccine, BCG (Bacillus Calmette-GuΓ©rin), developed in 1921, protects infants against severe TB but provides limited protection in adults against pulmonary TB. The pipeline includes several promising candidates: M72/AS01E showed 50% efficacy in Phase 2b trials (the first TB vaccine to show significant adult protection in decades), VPM1002 (recombinant BCG) is in Phase 3 trials, and MTBVAC (live attenuated M. tuberculosis) represents a new generation of vaccines. This tracker monitors these leading candidates plus emerging approaches including therapeutic vaccines, mRNA platforms, and viral vectors targeting both prevention and treatment of latent and active TB.

TB Vaccines by Development Phase